Global Oligonucleotides
Global Oligonucleotides

Oligonucleotides Comprehensive Study by Type (DNA Oligos, RNA Oligos), Application (Gene expression experiments,, Probes for microarrays, Antisense technologies, In situ hybridization, Drug carriers), End Users (Pharmaceuticals, Research institutes, Diagnostic centers), Service type (Custom oligos, Predesigned oligos, Oligo synthesis) Players and Region - Global Market Outlook to 2024

Oligonucleotides Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 227 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The study covers a detailed analysis segmented by key business segments i.e. by type (DNA Oligos and RNA Oligos) , by application (Gene expression experiments,, Probes for microarrays, Antisense technologies, In situ hybridization and Drug carriers) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oligonucleotides market throughout the predicted period.

The competition is expected to become even more intense in the coming years with the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Oligonucleotides market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • ThermoFisher (United States)
  • Eurofins Genomics (Germany)
  • AM Chemicals (United States)
  • TriLink BioTechnologies (United States)
  • Sigma-Aldrich (United States)
  • TAG Copenhagen (Denmark)
  • Bioneer (South Korea)
  • Biolegio (Netherlands)
  • IDT (United States)
  • Ella Biotech (Germany)


Market Overview:
In May 2019, Thermo Fisher Scientific Inc. has acquired Brammer Bio which manufactures viral vector for gene and cell therapy.

Market Trend
Adoption of Advanced Strategies which Enhanced the Direct Selling
Restraints
  • Development of in House Oligonucleotides Which May Affect the Sales of Service Provider
  • Lack of Skilled Labor

Opportunities
Rising Research and Development for Novel Products and Increasing Investments in R&Ds

Key highlights of the Global Oligonucleotides market Study:
• CAGR of the market during the forecast period 2018-2024
• Detailed information on factors that will accelerate the growth of the Oligonucleotides market for the next five years.
• Forecast of the Global Oligonucleotides market size and its contribution to the parent market by type, application and by country.
• Insights on upcoming trends and changes in consumer behaviour
• Uncovering market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Oligonucleotides Players

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Oligonucleotides market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Oligonucleotides market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • DNA Oligos
  • RNA Oligos
By Application
  • Gene expression experiments,
  • Probes for microarrays
  • Antisense technologies
  • In situ hybridization
  • Drug carriers
By End Users
  • Pharmaceuticals
  • Research institutes
  • Diagnostic centers

By Service type
  • Custom oligos
  • Predesigned oligos
  • Oligo synthesis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for High end Customized Oligos
      • 3.2.2. Decreasing Costs of Sequencing Leading to Customized Nucleotides
    • 3.3. Market Challenges
      • 3.3.1. Lack of Available Resources
    • 3.4. Market Trends
      • 3.4.1. Adoption of Advanced Strategies which Enhanced the Direct Selling
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oligonucleotides, by Type, Application, End Users, Service type and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Oligonucleotides (Value)
      • 5.2.1. Global Oligonucleotides by: Type (Value)
        • 5.2.1.1. DNA Oligos
        • 5.2.1.2. RNA Oligos
      • 5.2.2. Global Oligonucleotides by: Application (Value)
        • 5.2.2.1. Gene expression experiments,
        • 5.2.2.2. Probes for microarrays
        • 5.2.2.3. Antisense technologies
        • 5.2.2.4. In situ hybridization
        • 5.2.2.5. Drug carriers
      • 5.2.3. Global Oligonucleotides by: End Users (Value)
        • 5.2.3.1. Pharmaceuticals
        • 5.2.3.2. Research institutes
        • 5.2.3.3. Diagnostic centers
      • 5.2.4. Global Oligonucleotides by: Service type (Value)
        • 5.2.4.1. Custom oligos
        • 5.2.4.2. Predesigned oligos
        • 5.2.4.3. Oligo synthesis
      • 5.2.5. Global Oligonucleotides Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Oligonucleotides: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ThermoFisher (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eurofins Genomics (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AM Chemicals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. TriLink BioTechnologies (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sigma-Aldrich (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. TAG Copenhagen (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bioneer (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biolegio (Netherlands)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. IDT (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ella Biotech (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oligonucleotides Sale, by Type, Application, End Users, Service type and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Oligonucleotides (Value)
      • 7.2.1. Global Oligonucleotides by: Type (Value)
        • 7.2.1.1. DNA Oligos
        • 7.2.1.2. RNA Oligos
      • 7.2.2. Global Oligonucleotides by: Application (Value)
        • 7.2.2.1. Gene expression experiments,
        • 7.2.2.2. Probes for microarrays
        • 7.2.2.3. Antisense technologies
        • 7.2.2.4. In situ hybridization
        • 7.2.2.5. Drug carriers
      • 7.2.3. Global Oligonucleotides by: End Users (Value)
        • 7.2.3.1. Pharmaceuticals
        • 7.2.3.2. Research institutes
        • 7.2.3.3. Diagnostic centers
      • 7.2.4. Global Oligonucleotides by: Service type (Value)
        • 7.2.4.1. Custom oligos
        • 7.2.4.2. Predesigned oligos
        • 7.2.4.3. Oligo synthesis
      • 7.2.5. Global Oligonucleotides Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oligonucleotides: by Type(USD Million)
  • Table 2. Oligonucleotides DNA Oligos , by Region USD Million (2013-2018)
  • Table 3. Oligonucleotides RNA Oligos , by Region USD Million (2013-2018)
  • Table 4. Oligonucleotides: by Application(USD Million)
  • Table 5. Oligonucleotides Gene expression experiments, , by Region USD Million (2013-2018)
  • Table 6. Oligonucleotides Probes for microarrays , by Region USD Million (2013-2018)
  • Table 7. Oligonucleotides Antisense technologies , by Region USD Million (2013-2018)
  • Table 8. Oligonucleotides In situ hybridization , by Region USD Million (2013-2018)
  • Table 9. Oligonucleotides Drug carriers , by Region USD Million (2013-2018)
  • Table 10. Oligonucleotides: by End Users(USD Million)
  • Table 11. Oligonucleotides Pharmaceuticals , by Region USD Million (2013-2018)
  • Table 12. Oligonucleotides Research institutes , by Region USD Million (2013-2018)
  • Table 13. Oligonucleotides Diagnostic centers , by Region USD Million (2013-2018)
  • Table 14. Oligonucleotides: by Service type(USD Million)
  • Table 15. Oligonucleotides Custom oligos , by Region USD Million (2013-2018)
  • Table 16. Oligonucleotides Predesigned oligos , by Region USD Million (2013-2018)
  • Table 17. Oligonucleotides Oligo synthesis , by Region USD Million (2013-2018)
  • Table 18. South America Oligonucleotides, by Country USD Million (2013-2018)
  • Table 19. South America Oligonucleotides, by Type USD Million (2013-2018)
  • Table 20. South America Oligonucleotides, by Application USD Million (2013-2018)
  • Table 21. South America Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 22. South America Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 23. Brazil Oligonucleotides, by Type USD Million (2013-2018)
  • Table 24. Brazil Oligonucleotides, by Application USD Million (2013-2018)
  • Table 25. Brazil Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 26. Brazil Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 27. Argentina Oligonucleotides, by Type USD Million (2013-2018)
  • Table 28. Argentina Oligonucleotides, by Application USD Million (2013-2018)
  • Table 29. Argentina Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 30. Argentina Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 31. Rest of South America Oligonucleotides, by Type USD Million (2013-2018)
  • Table 32. Rest of South America Oligonucleotides, by Application USD Million (2013-2018)
  • Table 33. Rest of South America Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 34. Rest of South America Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 35. Asia Pacific Oligonucleotides, by Country USD Million (2013-2018)
  • Table 36. Asia Pacific Oligonucleotides, by Type USD Million (2013-2018)
  • Table 37. Asia Pacific Oligonucleotides, by Application USD Million (2013-2018)
  • Table 38. Asia Pacific Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 39. Asia Pacific Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 40. China Oligonucleotides, by Type USD Million (2013-2018)
  • Table 41. China Oligonucleotides, by Application USD Million (2013-2018)
  • Table 42. China Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 43. China Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 44. Japan Oligonucleotides, by Type USD Million (2013-2018)
  • Table 45. Japan Oligonucleotides, by Application USD Million (2013-2018)
  • Table 46. Japan Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 47. Japan Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 48. India Oligonucleotides, by Type USD Million (2013-2018)
  • Table 49. India Oligonucleotides, by Application USD Million (2013-2018)
  • Table 50. India Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 51. India Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 52. South Korea Oligonucleotides, by Type USD Million (2013-2018)
  • Table 53. South Korea Oligonucleotides, by Application USD Million (2013-2018)
  • Table 54. South Korea Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 55. South Korea Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 56. Taiwan Oligonucleotides, by Type USD Million (2013-2018)
  • Table 57. Taiwan Oligonucleotides, by Application USD Million (2013-2018)
  • Table 58. Taiwan Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 59. Taiwan Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 60. Australia Oligonucleotides, by Type USD Million (2013-2018)
  • Table 61. Australia Oligonucleotides, by Application USD Million (2013-2018)
  • Table 62. Australia Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 63. Australia Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific Oligonucleotides, by Type USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Oligonucleotides, by Application USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 68. Europe Oligonucleotides, by Country USD Million (2013-2018)
  • Table 69. Europe Oligonucleotides, by Type USD Million (2013-2018)
  • Table 70. Europe Oligonucleotides, by Application USD Million (2013-2018)
  • Table 71. Europe Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 72. Europe Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 73. Germany Oligonucleotides, by Type USD Million (2013-2018)
  • Table 74. Germany Oligonucleotides, by Application USD Million (2013-2018)
  • Table 75. Germany Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 76. Germany Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 77. France Oligonucleotides, by Type USD Million (2013-2018)
  • Table 78. France Oligonucleotides, by Application USD Million (2013-2018)
  • Table 79. France Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 80. France Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 81. Italy Oligonucleotides, by Type USD Million (2013-2018)
  • Table 82. Italy Oligonucleotides, by Application USD Million (2013-2018)
  • Table 83. Italy Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 84. Italy Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 85. United Kingdom Oligonucleotides, by Type USD Million (2013-2018)
  • Table 86. United Kingdom Oligonucleotides, by Application USD Million (2013-2018)
  • Table 87. United Kingdom Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 88. United Kingdom Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 89. Netherlands Oligonucleotides, by Type USD Million (2013-2018)
  • Table 90. Netherlands Oligonucleotides, by Application USD Million (2013-2018)
  • Table 91. Netherlands Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 92. Netherlands Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 93. Rest of Europe Oligonucleotides, by Type USD Million (2013-2018)
  • Table 94. Rest of Europe Oligonucleotides, by Application USD Million (2013-2018)
  • Table 95. Rest of Europe Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 96. Rest of Europe Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 97. MEA Oligonucleotides, by Country USD Million (2013-2018)
  • Table 98. MEA Oligonucleotides, by Type USD Million (2013-2018)
  • Table 99. MEA Oligonucleotides, by Application USD Million (2013-2018)
  • Table 100. MEA Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 101. MEA Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 102. Middle East Oligonucleotides, by Type USD Million (2013-2018)
  • Table 103. Middle East Oligonucleotides, by Application USD Million (2013-2018)
  • Table 104. Middle East Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 105. Middle East Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 106. Africa Oligonucleotides, by Type USD Million (2013-2018)
  • Table 107. Africa Oligonucleotides, by Application USD Million (2013-2018)
  • Table 108. Africa Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 109. Africa Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 110. North America Oligonucleotides, by Country USD Million (2013-2018)
  • Table 111. North America Oligonucleotides, by Type USD Million (2013-2018)
  • Table 112. North America Oligonucleotides, by Application USD Million (2013-2018)
  • Table 113. North America Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 114. North America Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 115. United States Oligonucleotides, by Type USD Million (2013-2018)
  • Table 116. United States Oligonucleotides, by Application USD Million (2013-2018)
  • Table 117. United States Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 118. United States Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 119. Canada Oligonucleotides, by Type USD Million (2013-2018)
  • Table 120. Canada Oligonucleotides, by Application USD Million (2013-2018)
  • Table 121. Canada Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 122. Canada Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 123. Mexico Oligonucleotides, by Type USD Million (2013-2018)
  • Table 124. Mexico Oligonucleotides, by Application USD Million (2013-2018)
  • Table 125. Mexico Oligonucleotides, by End Users USD Million (2013-2018)
  • Table 126. Mexico Oligonucleotides, by Service type USD Million (2013-2018)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Oligonucleotides: by Type(USD Million)
  • Table 138. Oligonucleotides DNA Oligos , by Region USD Million (2019-2024)
  • Table 139. Oligonucleotides RNA Oligos , by Region USD Million (2019-2024)
  • Table 140. Oligonucleotides: by Application(USD Million)
  • Table 141. Oligonucleotides Gene expression experiments, , by Region USD Million (2019-2024)
  • Table 142. Oligonucleotides Probes for microarrays , by Region USD Million (2019-2024)
  • Table 143. Oligonucleotides Antisense technologies , by Region USD Million (2019-2024)
  • Table 144. Oligonucleotides In situ hybridization , by Region USD Million (2019-2024)
  • Table 145. Oligonucleotides Drug carriers , by Region USD Million (2019-2024)
  • Table 146. Oligonucleotides: by End Users(USD Million)
  • Table 147. Oligonucleotides Pharmaceuticals , by Region USD Million (2019-2024)
  • Table 148. Oligonucleotides Research institutes , by Region USD Million (2019-2024)
  • Table 149. Oligonucleotides Diagnostic centers , by Region USD Million (2019-2024)
  • Table 150. Oligonucleotides: by Service type(USD Million)
  • Table 151. Oligonucleotides Custom oligos , by Region USD Million (2019-2024)
  • Table 152. Oligonucleotides Predesigned oligos , by Region USD Million (2019-2024)
  • Table 153. Oligonucleotides Oligo synthesis , by Region USD Million (2019-2024)
  • Table 154. South America Oligonucleotides, by Country USD Million (2019-2024)
  • Table 155. South America Oligonucleotides, by Type USD Million (2019-2024)
  • Table 156. South America Oligonucleotides, by Application USD Million (2019-2024)
  • Table 157. South America Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 158. South America Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 159. Brazil Oligonucleotides, by Type USD Million (2019-2024)
  • Table 160. Brazil Oligonucleotides, by Application USD Million (2019-2024)
  • Table 161. Brazil Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 162. Brazil Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 163. Argentina Oligonucleotides, by Type USD Million (2019-2024)
  • Table 164. Argentina Oligonucleotides, by Application USD Million (2019-2024)
  • Table 165. Argentina Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 166. Argentina Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 167. Rest of South America Oligonucleotides, by Type USD Million (2019-2024)
  • Table 168. Rest of South America Oligonucleotides, by Application USD Million (2019-2024)
  • Table 169. Rest of South America Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 170. Rest of South America Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 171. Asia Pacific Oligonucleotides, by Country USD Million (2019-2024)
  • Table 172. Asia Pacific Oligonucleotides, by Type USD Million (2019-2024)
  • Table 173. Asia Pacific Oligonucleotides, by Application USD Million (2019-2024)
  • Table 174. Asia Pacific Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 175. Asia Pacific Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 176. China Oligonucleotides, by Type USD Million (2019-2024)
  • Table 177. China Oligonucleotides, by Application USD Million (2019-2024)
  • Table 178. China Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 179. China Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 180. Japan Oligonucleotides, by Type USD Million (2019-2024)
  • Table 181. Japan Oligonucleotides, by Application USD Million (2019-2024)
  • Table 182. Japan Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 183. Japan Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 184. India Oligonucleotides, by Type USD Million (2019-2024)
  • Table 185. India Oligonucleotides, by Application USD Million (2019-2024)
  • Table 186. India Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 187. India Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 188. South Korea Oligonucleotides, by Type USD Million (2019-2024)
  • Table 189. South Korea Oligonucleotides, by Application USD Million (2019-2024)
  • Table 190. South Korea Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 191. South Korea Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 192. Taiwan Oligonucleotides, by Type USD Million (2019-2024)
  • Table 193. Taiwan Oligonucleotides, by Application USD Million (2019-2024)
  • Table 194. Taiwan Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 195. Taiwan Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 196. Australia Oligonucleotides, by Type USD Million (2019-2024)
  • Table 197. Australia Oligonucleotides, by Application USD Million (2019-2024)
  • Table 198. Australia Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 199. Australia Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 200. Rest of Asia-Pacific Oligonucleotides, by Type USD Million (2019-2024)
  • Table 201. Rest of Asia-Pacific Oligonucleotides, by Application USD Million (2019-2024)
  • Table 202. Rest of Asia-Pacific Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 203. Rest of Asia-Pacific Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 204. Europe Oligonucleotides, by Country USD Million (2019-2024)
  • Table 205. Europe Oligonucleotides, by Type USD Million (2019-2024)
  • Table 206. Europe Oligonucleotides, by Application USD Million (2019-2024)
  • Table 207. Europe Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 208. Europe Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 209. Germany Oligonucleotides, by Type USD Million (2019-2024)
  • Table 210. Germany Oligonucleotides, by Application USD Million (2019-2024)
  • Table 211. Germany Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 212. Germany Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 213. France Oligonucleotides, by Type USD Million (2019-2024)
  • Table 214. France Oligonucleotides, by Application USD Million (2019-2024)
  • Table 215. France Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 216. France Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 217. Italy Oligonucleotides, by Type USD Million (2019-2024)
  • Table 218. Italy Oligonucleotides, by Application USD Million (2019-2024)
  • Table 219. Italy Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 220. Italy Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 221. United Kingdom Oligonucleotides, by Type USD Million (2019-2024)
  • Table 222. United Kingdom Oligonucleotides, by Application USD Million (2019-2024)
  • Table 223. United Kingdom Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 224. United Kingdom Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 225. Netherlands Oligonucleotides, by Type USD Million (2019-2024)
  • Table 226. Netherlands Oligonucleotides, by Application USD Million (2019-2024)
  • Table 227. Netherlands Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 228. Netherlands Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 229. Rest of Europe Oligonucleotides, by Type USD Million (2019-2024)
  • Table 230. Rest of Europe Oligonucleotides, by Application USD Million (2019-2024)
  • Table 231. Rest of Europe Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 232. Rest of Europe Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 233. MEA Oligonucleotides, by Country USD Million (2019-2024)
  • Table 234. MEA Oligonucleotides, by Type USD Million (2019-2024)
  • Table 235. MEA Oligonucleotides, by Application USD Million (2019-2024)
  • Table 236. MEA Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 237. MEA Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 238. Middle East Oligonucleotides, by Type USD Million (2019-2024)
  • Table 239. Middle East Oligonucleotides, by Application USD Million (2019-2024)
  • Table 240. Middle East Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 241. Middle East Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 242. Africa Oligonucleotides, by Type USD Million (2019-2024)
  • Table 243. Africa Oligonucleotides, by Application USD Million (2019-2024)
  • Table 244. Africa Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 245. Africa Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 246. North America Oligonucleotides, by Country USD Million (2019-2024)
  • Table 247. North America Oligonucleotides, by Type USD Million (2019-2024)
  • Table 248. North America Oligonucleotides, by Application USD Million (2019-2024)
  • Table 249. North America Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 250. North America Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 251. United States Oligonucleotides, by Type USD Million (2019-2024)
  • Table 252. United States Oligonucleotides, by Application USD Million (2019-2024)
  • Table 253. United States Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 254. United States Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 255. Canada Oligonucleotides, by Type USD Million (2019-2024)
  • Table 256. Canada Oligonucleotides, by Application USD Million (2019-2024)
  • Table 257. Canada Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 258. Canada Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 259. Mexico Oligonucleotides, by Type USD Million (2019-2024)
  • Table 260. Mexico Oligonucleotides, by Application USD Million (2019-2024)
  • Table 261. Mexico Oligonucleotides, by End Users USD Million (2019-2024)
  • Table 262. Mexico Oligonucleotides, by Service type USD Million (2019-2024)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oligonucleotides: by Type USD Million (2013-2018)
  • Figure 5. Global Oligonucleotides: by Application USD Million (2013-2018)
  • Figure 6. Global Oligonucleotides: by End Users USD Million (2013-2018)
  • Figure 7. Global Oligonucleotides: by Service type USD Million (2013-2018)
  • Figure 8. South America Oligonucleotides Share (%), by Country
  • Figure 9. Asia Pacific Oligonucleotides Share (%), by Country
  • Figure 10. Europe Oligonucleotides Share (%), by Country
  • Figure 11. MEA Oligonucleotides Share (%), by Country
  • Figure 12. North America Oligonucleotides Share (%), by Country
  • Figure 13. Global Oligonucleotides share by Players 2018 (%)
  • Figure 14. Global Oligonucleotides share by Players (Top 3) 2018(%)
  • Figure 15. Global Oligonucleotides share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. ThermoFisher (United States) Revenue, Net Income and Gross profit
  • Figure 18. ThermoFisher (United States) Revenue: by Geography 2018
  • Figure 19. Eurofins Genomics (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Eurofins Genomics (Germany) Revenue: by Geography 2018
  • Figure 21. AM Chemicals (United States) Revenue, Net Income and Gross profit
  • Figure 22. AM Chemicals (United States) Revenue: by Geography 2018
  • Figure 23. TriLink BioTechnologies (United States) Revenue, Net Income and Gross profit
  • Figure 24. TriLink BioTechnologies (United States) Revenue: by Geography 2018
  • Figure 25. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sigma-Aldrich (United States) Revenue: by Geography 2018
  • Figure 27. TAG Copenhagen (Denmark) Revenue, Net Income and Gross profit
  • Figure 28. TAG Copenhagen (Denmark) Revenue: by Geography 2018
  • Figure 29. Bioneer (South Korea) Revenue, Net Income and Gross profit
  • Figure 30. Bioneer (South Korea) Revenue: by Geography 2018
  • Figure 31. Biolegio (Netherlands) Revenue, Net Income and Gross profit
  • Figure 32. Biolegio (Netherlands) Revenue: by Geography 2018
  • Figure 33. IDT (United States) Revenue, Net Income and Gross profit
  • Figure 34. IDT (United States) Revenue: by Geography 2018
  • Figure 35. Ella Biotech (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Ella Biotech (Germany) Revenue: by Geography 2018
  • Figure 37. Global Oligonucleotides: by Type USD Million (2019-2024)
  • Figure 38. Global Oligonucleotides: by Application USD Million (2019-2024)
  • Figure 39. Global Oligonucleotides: by End Users USD Million (2019-2024)
  • Figure 40. Global Oligonucleotides: by Service type USD Million (2019-2024)
  • Figure 41. South America Oligonucleotides Share (%), by Country
  • Figure 42. Asia Pacific Oligonucleotides Share (%), by Country
  • Figure 43. Europe Oligonucleotides Share (%), by Country
  • Figure 44. MEA Oligonucleotides Share (%), by Country
  • Figure 45. North America Oligonucleotides Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • ThermoFisher (United States)
  • Eurofins Genomics (Germany)
  • AM Chemicals (United States)
  • TriLink BioTechnologies (United States)
  • Sigma-Aldrich (United States)
  • TAG Copenhagen (Denmark)
  • Bioneer (South Korea)
  • Biolegio (Netherlands)
  • IDT (United States)
  • Ella Biotech (Germany)
Additional players considered in the study are as follows:
SGS DNA (Switzerland) , Syntezza Bioscience (Israel) , Exiqon (Denmark) , Microsynth AG (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation